Ziarco, which develops therapeutics for inflammatory skin diseases, raised $33.1m in series B funding featuring Pfizer Venture Investments and Amgen Ventures.

UK-based biotechnology company Ziarco Group raised $33.1m in series B funding on Monday with involvement from the corporate venturing units of drugs company Pfizer and biotech company Amgen.

Lundbeckfond Ventures, an investment subsidiary of Denmark-based pharmaceutical company Lundbeck, venture capital firm New Enterprise Associates and private equity firm BVF Partners joined Pfizer Venture Investments and Amgen Ventures in the round.

Ziarco is focused on developing treatments for inflammatory skin diseases. It raised $7.6m in a 2012 series A round backed…